• Join
  • Login
  • Contact

Search abstracts

Cost analysis of new antibiotics against serious gram - infections used in intensive care units: cefiderocol vs meropenem/varbobactam

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-026
  • By: DI NARDO, Giovanni Battista (UOC FARMACIA, ASL Frosinone, Italy)
  • Co-author(s): Dr Giovanni Battista Di Nardo, Hospital Pharmacist
    Dr Noemi Pagnotta, UOC Farmacia
    Dr Fulvio Ferrante, UOC Farmacia
  • Abstract:

    Background Information:Infections caused by Gram-resistant bacteria are one of the main causes of mortality in patients in intensive care units. Eradication of these germs has a serious economic impact on public health budget. Cefiderocol and the combination Meropenem/Vaborbactam are state-of-the-art antibiotics used to treat such infections in..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses